Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTX-09
- Development stage
- Preclinical
- Lead developer
- Leal Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**LTX-09** is an investigational **oral immediate-release small-molecule non-opioid analgesic** in **preclinical** development by **Acura**. Based on Acura's pipeline descriptions, it appears to be a **LIMITX-formulated pain candidate** intended for non-opioid analgesia, but the **specific active ingredient and molecular target have not been publicly disclosed**. The program is therefore best understood as a proprietary abuse-deterrent or misuse-limiting immediate-release analgesic formulation concept within Acura's LIMITX platform rather than a fully characterized named active pharmaceutical ingredient.
- Other names
- LIMITX non-opioid immediate-release candidate
Beyond the preview
Go deeper on LTX-09.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTX-09.